Immunotherapy has emerged as an eminent and effective modality in the treatment of
cancer. However, current cancer immunotherapies lack spatial and temporal control …

Background: The treatment of non-small-cell lung carcinoma (NSCLC) has changed
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …

Evidence from real-world clinical settings is lacking with regard to first-line immunotherapy
plus chemotherapy for the treatment of non-small cell lung cancer (NSCLC). Our aim was to …

Immune-oncologic (IO) therapy has revolutionized the treatment and management of
oncologic disease. Immunotherapy functions by enhancing the host immune-systems ability …

Background and Objective Although anti-programmed cell death protein 1 (PD-1) antibodies
have exerted remarkable anticancer activity in non-small cell lung cancer (NSCLC), it …

Immune checkpoint inhibitors (ICIs) targeting programmed death 1 (PD-1) and PD-ligand 1
(PD-L1) quickly subverted the standard of treatment in Non-Small Cell Lung Cancer …

Lung cancer incidence has increased worldwide over the past decades, with non‐small cell
lung cancer (NSCLC) accounting for the vast majority (85%) of lung cancer specimens. It is …

Objective Pembrolizumab has become an integral first line therapeutic agent for non-small
cell lung cancer (NSCLC), but its potential predictive role in clinical and molecular …

Aim: To determine real-world outcomes with first-line pembrolizumab monotherapy for
metastatic non-small-cell lung cancer with PD-L1 tumor expression≥ 50%. Methods: This …

Background Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the
standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here …